Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancerChristophe Massard, Kim Nguyen Chi, Daniel Castellano, et al.Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.JAMA Oncology|December 2, 2017
Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal CancerAllen S Ho, Sungjin Kim, Mourad Tighiouart, et al.Targeted Oncology|August 10, 2020
Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in CancerEric Vail, Jianbo Song, Jing Xu, et al.Oncology|June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid TumorsDavid Hong, Drew Rasco, Michael Veeder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.Journal for Immunotherapy of Cancer|October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trialJoël Guigay, Keun-Wook Lee, Manish R Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid TumorsJosep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.Pageof 6